Organization
Department of Medical Oncology, Fudan University Shanghai Cancer Center
1 abstract
Abstract
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,